Action of pirenzepine, a new muscarinic antagonist drug, on human pancreatic secretion.
The action of a new muscarinic antagonist drug on the pancreatic secretion has been studied in 12 healthy subjects. A stable pancreatic secretory plateau was obtained with submaximal hormonal stimulation (0.125 CU/kg/h secretin: 30 ng/kg/h caerulein). The highest dose of pirenzepine (40 mg) inhibited both volume and enzymatic concentration and output (-72.2% and -77.9% of plateau value for chymotrypsin and lipase output, respectively, 30 min after pirenzepine injection). The inhibition appeared immediately, lasted for more than 60 min, and was dose-related. The calcium dose-response curve paralleled those of lipase and chymotrypsin outputs. These results were comparable to those obtained with other anti-acetylcholine drugs and may be associated with the action of certain doses of ethanol on pancreatic secretion. In contrast, the lowest pirenzepine dose used (10 mg) induced a delayed stimulation of bicarbonate output, and bicarbonate concentration was not altered.
D000328:Adult; D000368:Aged; D001570:Benzodiazepinones / Q000494:pharmacology*; D001639:Bicarbonates / Q000378:metabolism; D002108:Ceruletide / Q000494:pharmacology; D002918:Chymotrypsin / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004386:Duodenum; D005260:Female; D006801:Humans; D007419:Intestinal Secretions / Q000187:drug effects; D008049:Lipase / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000378:metabolism*; D010890:Pirenzepine; D011976:Receptors, Muscarinic / Q000187:drug effects*; D012633:Secretin / Q000494:pharmacology
D001570:Benzodiazepinones; D001639:Bicarbonates; D011976:Receptors, Muscarinic; D012633:Secretin; D010890:Pirenzepine; D002108:Ceruletide; D008049:Lipase; D002918:Chymotrypsin